Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James P Allison

Showing results (41-50 of 226) with videos related to

Pageof 23
Sort By:
Current Opinion in Immunology|February 2, 2010
Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS)Tyler R Simpson, Sergio A Quezada, James P Allison
Cancer Immunity|August 17, 2012
Monoclonal antibodies in cancer therapyAndrew M Scott, James P Allison, Jedd D Wolchok
Plos Biology|September 22, 2010
Attenuated T cell responses to a high-potency ligand in vivoEmily Corse, Rachel A Gottschalk, Michelle Krogsgaard, et al.
The Journal of Experimental Medicine|May 11, 2021
LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapyNaveen Sharma, Oluwatomisin T Atolagbe, Zhongqi Ge, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 18, 2010
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsMichael A Curran, Welby Montalvo, Hideo Yagita, et al.
Cancer Immunity|August 17, 2012
An open invitation to the cancer immunology communityPramod K Srivastava, Vincenzo Cerundolo, Alexander Knuth, et al.
Nature Reviews. Cancer|October 25, 2011
Novel cancer immunotherapy agents with survival benefit: recent successes and next stepsPadmanee Sharma, Klaus Wagner, Jedd D Wolchok, et al.
Immunity|September 11, 2004
B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapseTsvetelina Pentcheva-Hoang, Jackson G Egen, Kathleen Wojnoonski, et al.
Blood Cancer Discovery|January 11, 2022
Checkpoint Blockade + Chemotherapy: the Right Combination for AML?Spencer C Wei, James J Mancuso, Naval Daver, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2007
Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availabilityTsvetelina Pentcheva-Hoang, Lieping Chen, Drew M Pardoll, et al.
Pageof 23

Showing results (41-50 of 226) with videos related to

Sort By:
Pageof 23
Current Opinion in Immunology|February 2, 2010
Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS)Tyler R Simpson, Sergio A Quezada, James P Allison
Cancer Immunity|August 17, 2012
Monoclonal antibodies in cancer therapyAndrew M Scott, James P Allison, Jedd D Wolchok
Plos Biology|September 22, 2010
Attenuated T cell responses to a high-potency ligand in vivoEmily Corse, Rachel A Gottschalk, Michelle Krogsgaard, et al.
The Journal of Experimental Medicine|May 11, 2021
LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapyNaveen Sharma, Oluwatomisin T Atolagbe, Zhongqi Ge, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 18, 2010
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsMichael A Curran, Welby Montalvo, Hideo Yagita, et al.
Cancer Immunity|August 17, 2012
An open invitation to the cancer immunology communityPramod K Srivastava, Vincenzo Cerundolo, Alexander Knuth, et al.
Nature Reviews. Cancer|October 25, 2011
Novel cancer immunotherapy agents with survival benefit: recent successes and next stepsPadmanee Sharma, Klaus Wagner, Jedd D Wolchok, et al.
Immunity|September 11, 2004
B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapseTsvetelina Pentcheva-Hoang, Jackson G Egen, Kathleen Wojnoonski, et al.
Blood Cancer Discovery|January 11, 2022
Checkpoint Blockade + Chemotherapy: the Right Combination for AML?Spencer C Wei, James J Mancuso, Naval Daver, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2007
Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availabilityTsvetelina Pentcheva-Hoang, Lieping Chen, Drew M Pardoll, et al.
Pageof 23